Free Newsletter
Deal adds drug analysis to Millipore offerings
Millipore is establishing a beachhead extending its reach into Europe, the home turf of competitor Sartorius Stedim Biotech, through the acquisition of U.K.-based BioAnaLab, a specialist service provider for biologic drug and vaccine analysis.
The deal lets Millipore further establish its biopharmaceutical services business and fortify its status as an outsource partner, according to a company announcement. BioAnaLab brings GMP support testing capabilities and its customer base to the deal. The Oxford company was spun out of the University of Oxford in 2002.
For its part, Goettingen, Germany-based Sartorius Stedim announced in July that it is partnering with cell culture media specialist SAFC Biosciences to provide fluid management and liquid/powder system solutions for upstream and downstream processing. The deal is expected to further the German company's offerings of single-use bioprocess technology.
- see the Millipore announcement
- here's the Sartorius Stedim release
Related Articles:
Millipore expands in Massachusetts
Disposable bioreactor boasts impeller stirring
Millipore, Astellas ink contract
Millipore streamlines, closes plants
Millipore expands in Missouri
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: